NCT02898961

Brief Summary

Low first-dose peak serum concentrations of amikacin and gentamicin are commonly reported in ICU patients. The present study aimed to assess whether 30 mg/kg amikacin or 8 mg/kg gentamicin achieved target concentrations in ICU patients with severe sepsis.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
63

participants targeted

Target at P25-P50 for phase_4 sepsis

Timeline
Completed

Started Oct 2014

Typical duration for phase_4 sepsis

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2014

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

September 1, 2016

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 13, 2016

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2016

Completed
Last Updated

November 21, 2025

Status Verified

December 1, 2020

Enrollment Period

2.3 years

First QC Date

September 1, 2016

Last Update Submit

November 18, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Presence/absence of target peak serum concentration of aminosides

    Achievement of targeted peak serum concentration?

    30 minutes after the end of the infusion.

Study Arms (1)

The study population

EXPERIMENTAL

ICU patients with severe sepsis treated with aminoglycosides were recruited. Intervention: 30 mg/kg amikacin or 8 mg/kg gentamicin

Drug: 30 mg/kg amikacin or 8 mg/kg gentamicin

Interventions

In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis. In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion.

The study population

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ICU patient with severe sepsis
  • Treated with aminoglycosides

You may not qualify if:

  • Renal replacement therapy
  • Allergy to aminoglycosides
  • Confirmed and/or suspected to have myasthenia
  • ICU-acquired neuromuscular disorder
  • Under guardianship
  • Prisoners
  • The patient has already participated in the present protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, Lavigne JP, Allaouchiche B, Lefrant JY, Roberts JA, Muller L. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother. 2016 Jan;71(1):208-12. doi: 10.1093/jac/dkv291. Epub 2015 Oct 1.

MeSH Terms

Conditions

Sepsis

Interventions

AmikacinGentamicins

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

KanamycinAminoglycosidesGlycosidesCarbohydrates

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 1, 2016

First Posted

September 13, 2016

Study Start

October 1, 2014

Primary Completion

December 31, 2016

Study Completion

December 31, 2016

Last Updated

November 21, 2025

Record last verified: 2020-12